Adaptimmune Therapeutics Plc Current ratio
Cos'è Current ratio di Adaptimmune Therapeutics Plc?
Current ratio di Adaptimmune Therapeutics Plc è 3.09
Qual è la definizione di Current ratio?
Il rapporto corrente è un rapporto di liquidità che misura se una società dispone o meno di risorse sufficienti per soddisfare i suoi obblighi a breve termine.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio di aziende nel Health Care settore su NASDAQ rispetto a Adaptimmune Therapeutics Plc
Cosa fa Adaptimmune Therapeutics Plc?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Aziende con current ratio simili a Adaptimmune Therapeutics Plc
- PT Aneka Tambang Tbk ha Current ratio di 3.09
- The a2 Milk ha Current ratio di 3.09
- Zevia PBC ha Current ratio di 3.09
- PF ha Current ratio di 3.09
- Pipeline Engineering ha Current ratio di 3.09
- Secoo Ltd ha Current ratio di 3.09
- Adaptimmune Therapeutics Plc ha Current ratio di 3.09
- Larsen & Toubro Infotech ha Current ratio di 3.09
- Beauce Gold Fields ha Current ratio di 3.09
- KEI Industries ha Current ratio di 3.09
- Sohu.com ha Current ratio di 3.09
- The Peria Karamalai Tea and Produce ha Current ratio di 3.09
- Graphite India ha Current ratio di 3.09